HIGHLIGHTS
SUMMARY
The assessment of tumor genetic alterations is currently crucial in oncological patient management and treatment decisions. The alterations in ctDNA can be considered as a biomarker, and these can allow to identify cancer patients from a group of healthy individuals, to evaluate the cancer mutational status, to assess the response to treatment, and to identify groups of patients with a poor prognosis. KRAS (Gly12Cys) was found in 2/29 (6.9%) patients, and EGFR (Arg255Gln), EGFR (Val592Ile), EGFR (Ala647Thr), EGFR (Leu858Arg), ALK (Pro254Thr), ALK (Trp288Ser), ALK (Glu797Lys), PIK3CA (Arg19Ile), PIK3CA (Arg852Pro), PIK3CA (Met1043Ile), ROS . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.